Narrative Integrity Audit™
Narrative Integrity Audit™
Clarity Before Scrutiny.
A senior-led diagnostic that examines whether your scientific evidence, regulatory position, medical claims, market access strategy, commercial messaging, and investment narrative remain consistent, defensible, and fit for purpose.
Identify material gaps, conflicting assumptions, and emerging risks before they affect critical decisions.
Why Alignment Fails Under Pressure
As life sciences organisations develop, specialist functions naturally approach the same product from different perspectives. Regulatory teams focus on evidence and compliance. Medical Affairs interprets clinical relevance. Market Access evaluates value. Commercial teams shape positioning. Investors assess opportunity and risk.
Each perspective is necessary. Problems arise when assumptions, claims, and strategic priorities develop independently without sufficient cross-functional scrutiny.
A regulatory position may be technically sound while the commercial narrative overstates the evidence. A compelling investment proposition may depend on assumptions that have not been adequately tested. Individually credible messages can become collectively inconsistent.
The Narrative Integrity Audit™ examines these connections, identifies material areas of misalignment, and provides a structured basis for corrective decisions.
Five Decision Lenses. One Coherent Position.
Regulatory Position
Are regulatory claims, evidence, and development assumptions sufficiently supported and consistent across relevant markets?
Medical Position
Do scientific interpretations, publications, and medical communications accurately reflect the available evidence?
Market Access Position
Are clinical value, economic assumptions and payer-facing claims coherent and defensible?
Commercial Position
Does product positioning accurately represent the evidence, differentiation, and intended market opportunity?
Investment Position
Can the investment narrative withstand scrutiny of the science, development strategy, commercial assumptions, and principal risks?
Board-Ready Output. Not Consultancy Slides.
The Audit provides a structured, decision-focused assessment to help leadership understand where alignment is strong, where assumptions need examination, and where corrective action may be necessary.
- Cross-functional review of the agreed evidence, claims, and strategic materials
- Identification of material inconsistencies, unsupported assumptions, and narrative risks
- Prioritised findings, including Red/Amber/Green risk classification
- Executive summary suitable for leadership discussion
- Practical recommendations, with proposed next steps and decision priorities
Timeframe: Agreed based on scope, complexity, and material availability.
Format: Executive findings document and senior-led discussion.
Audit Timing
The Narrative Integrity Audit™ is very valuable when organisations are approaching decisions or milestones that demand greater cross-functional scrutiny:
- Before regulatory submission
- Before major publication releases
- Before HTA or payer engagement
- Before Series B/C funding rounds or an IPO
- Before major product launches or global rollouts
Engagement Structure
The Audit is a defined-scope, senior-led diagnostic designed to provide clarity without unnecessary complexity or long-term commitments:
- Agree the scope, priorities, and materials for review
- Assess alignment and identify material risks
- Receive prioritised findings and practical recommendations
- Address identified gaps through targeted support, if required
- Implement recommendations independently or retain Amodaia for ongoing oversight
Clarity Before Commitment.
Whether you are preparing for a regulatory milestone, investor engagement, market access decision, or commercial launch, understanding where your evidence and strategic narratives diverge can help you avoid unnecessary risk.
The Narrative Integrity Audit™ brings independent, senior-led scrutiny to the connections that matter most.
